SG10201403109VA - Vaccine therapy for choroidal neovascularization - Google Patents

Vaccine therapy for choroidal neovascularization

Info

Publication number
SG10201403109VA
SG10201403109VA SG10201403109VA SG10201403109VA SG10201403109VA SG 10201403109V A SG10201403109V A SG 10201403109VA SG 10201403109V A SG10201403109V A SG 10201403109VA SG 10201403109V A SG10201403109V A SG 10201403109VA SG 10201403109V A SG10201403109V A SG 10201403109VA
Authority
SG
Singapore
Prior art keywords
choroidal neovascularization
vaccine therapy
vaccine
therapy
choroidal
Prior art date
Application number
SG10201403109VA
Other languages
English (en)
Inventor
Motokazu Tsujikawa
Yusuke Nakamura
Takuya Tsunoda
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of SG10201403109VA publication Critical patent/SG10201403109VA/en

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60N—SEATS SPECIALLY ADAPTED FOR VEHICLES; VEHICLE PASSENGER ACCOMMODATION NOT OTHERWISE PROVIDED FOR
    • B60N2/00—Seats specially adapted for vehicles; Arrangement or mounting of seats in vehicles
    • B60N2/02—Seats specially adapted for vehicles; Arrangement or mounting of seats in vehicles the seat or part thereof being movable, e.g. adjustable
    • B60N2/22—Seats specially adapted for vehicles; Arrangement or mounting of seats in vehicles the seat or part thereof being movable, e.g. adjustable the back-rest being adjustable
    • B60N2/225—Seats specially adapted for vehicles; Arrangement or mounting of seats in vehicles the seat or part thereof being movable, e.g. adjustable the back-rest being adjustable by cycloidal or planetary mechanisms
    • B60N2/2252—Seats specially adapted for vehicles; Arrangement or mounting of seats in vehicles the seat or part thereof being movable, e.g. adjustable the back-rest being adjustable by cycloidal or planetary mechanisms in which the central axis of the gearing lies inside the periphery of an orbital gear, e.g. one gear without sun gear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Aviation & Aerospace Engineering (AREA)
  • Transportation (AREA)
  • Mechanical Engineering (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Mycology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
SG10201403109VA 2009-06-11 2010-06-10 Vaccine therapy for choroidal neovascularization SG10201403109VA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2009140363 2009-06-11

Publications (1)

Publication Number Publication Date
SG10201403109VA true SG10201403109VA (en) 2014-10-30

Family

ID=43308696

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201403109VA SG10201403109VA (en) 2009-06-11 2010-06-10 Vaccine therapy for choroidal neovascularization
SG2011090933A SG176737A1 (en) 2009-06-11 2010-06-10 Vaccine therapy for choroidal neovascularization

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2011090933A SG176737A1 (en) 2009-06-11 2010-06-10 Vaccine therapy for choroidal neovascularization

Country Status (14)

Country Link
US (1) US8975229B2 (https=)
EP (1) EP2440226A4 (https=)
JP (1) JP5688587B2 (https=)
KR (1) KR20120038419A (https=)
CN (1) CN102802654A (https=)
AU (1) AU2010259797B2 (https=)
BR (1) BRPI1013025A2 (https=)
CA (1) CA2764562A1 (https=)
IL (1) IL216402A0 (https=)
MX (1) MX2011012659A (https=)
RU (1) RU2555345C2 (https=)
SG (2) SG10201403109VA (https=)
TW (1) TW201109029A (https=)
WO (1) WO2010143435A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4931154B2 (ja) 2005-02-28 2012-05-16 オンコセラピー・サイエンス株式会社 血管内皮増殖因子受容体１に由来するエピトープ・ペプチドおよびこれらのペプチドを含むワクチン
KR101493775B1 (ko) * 2007-02-16 2015-02-16 온코세라피 사이언스 가부시키가이샤 맥락막 신생혈관용 백신 치료
FR2990352A1 (fr) 2012-05-10 2013-11-15 Univ Paris 13 Composition immunogene comprenant un peptide derive du vegf et ses utilisations
US20200147194A1 (en) * 2017-05-19 2020-05-14 Keio University Peptide vaccine and peptide vaccine composition for cranial nerve disease

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861301A (en) 1992-02-20 1999-01-19 American Cayanamid Company Recombinant kinase insert domain containing receptor and gene encoding same
CN1701814A (zh) 1992-11-13 2005-11-30 马克斯普朗克科学促进协会 作为血管内皮生长因子受体的f1k－1
AU684498B2 (en) 1993-03-25 1997-12-18 Merck & Co., Inc. Inhibitor of vascular endothelial cell growth factor
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US6080728A (en) 1996-07-16 2000-06-27 Mixson; A. James Carrier: DNA complexes containing DNA encoding anti-angiogenic peptides and their use in gene therapy
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
JP3837748B2 (ja) 1997-01-17 2006-10-25 東亞合成株式会社 Ｖｅｇｆ結合性ポリペプチド
ES2292204T3 (es) 1997-06-18 2008-03-01 MERCK & CO., INC. (A NEW JERSEY CORP.) Receptor de tipo tirosina cinasa humano, kdr.
WO1999040118A1 (en) 1998-02-04 1999-08-12 Kyowa Hakko Kogyo Co., Ltd. Antibodies against human vegf receptor kdr
GB9804121D0 (en) 1998-02-26 1998-04-22 Cancer Res Campaign Tech Anti-angiogenic vaccines: materials and methods relating thereto
CA2328893A1 (en) 1998-05-20 1999-11-25 Kyowa Hakko Kogyo Co., Ltd. Vegf activity inhibitors
WO2001012809A2 (en) 1999-08-13 2001-02-22 Crucell Holland B.V. Heterodimeric vegf variants used for inhibiting angiogenesis
US7264810B2 (en) 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
AU2002362461A1 (en) 2001-10-01 2003-04-14 Targesome, Inc. Targeted therapeutic lipid constructs having cell surface targets
CU23178A1 (es) * 2002-04-15 2006-09-22 Ct Ingenieria Genetica Biotech INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA
DK2261249T3 (en) 2002-09-12 2015-02-16 Oncotherapy Science Inc KDR peptides and vaccines comprising the same
US8163726B2 (en) 2002-09-18 2012-04-24 University Of Pennsylvania Method of inhibiting choroidal neovascularization
CN1926551B (zh) 2003-10-27 2010-06-16 罗斯塔生化科技有限责任公司 用于基因沉默的siRNA的设计方法
JP2006215988A (ja) * 2005-02-07 2006-08-17 Ntt Docomo Kansai Inc 認証システム、携帯端末装置及び認証方法
JP4931154B2 (ja) * 2005-02-28 2012-05-16 オンコセラピー・サイエンス株式会社 血管内皮増殖因子受容体１に由来するエピトープ・ペプチドおよびこれらのペプチドを含むワクチン
US20060234941A1 (en) * 2005-04-15 2006-10-19 The Gov. Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Peptide epitopes of VEGFR-2/KDR that inhibit angiogenesis
JP2006315988A (ja) 2005-05-11 2006-11-24 Mototake Shimizu ケモカイン産生誘導効果を有する血管新生阻害物質
KR101493775B1 (ko) * 2007-02-16 2015-02-16 온코세라피 사이언스 가부시키가이샤 맥락막 신생혈관용 백신 치료
WO2008152816A1 (en) 2007-06-14 2008-12-18 Oncotherapy Science, Inc. Methods of identifying agents that modulate methylation of vegfr1 by smyd3
TWI436775B (zh) 2007-08-24 2014-05-11 Oncotherapy Science Inc 以抗原胜肽合併化療藥劑治療胰臟癌

Also Published As

Publication number Publication date
EP2440226A4 (en) 2013-09-18
WO2010143435A1 (en) 2010-12-16
US8975229B2 (en) 2015-03-10
SG176737A1 (en) 2012-01-30
RU2012100241A (ru) 2013-07-20
TW201109029A (en) 2011-03-16
IL216402A0 (en) 2012-01-31
EP2440226A1 (en) 2012-04-18
BRPI1013025A2 (pt) 2016-04-05
AU2010259797B2 (en) 2015-06-25
MX2011012659A (es) 2011-12-16
AU2010259797A1 (en) 2011-12-08
JP2012529423A (ja) 2012-11-22
JP5688587B2 (ja) 2015-03-25
KR20120038419A (ko) 2012-04-23
RU2555345C2 (ru) 2015-07-10
CN102802654A (zh) 2012-11-28
US20120156233A1 (en) 2012-06-21
CA2764562A1 (en) 2010-12-16

Similar Documents

Publication Publication Date Title
ZA201109164B (en) Vaccine
PL2444103T3 (pl) Szczepionka przeciwko rakowi szyjki macicy
GB201006165D0 (en) Vaccine
ZA201402071B (en) Vaccine therapy
IL216102A0 (en) Combined measles-malaria vaccine
IL216402A0 (en) Vaccine therapy for choroidal neovascularization
GB2467215B (en) Burkholderia components vaccine
IL200177A0 (en) Vaccine therapy for choroidal neovascularization
HRP20180744T1 (hr) Terapeutska cjepiva
IL228589A0 (en) Medical Care
IL217194A0 (en) Vaccine
GB201010500D0 (en) Therapeutic conjugates
HK1169335A (en) Vaccine therapy for choroidal neovascularization
ZA201205056B (en) Therapeutic use of protein-polymer conjugates
GB0802405D0 (en) Therapeutic vaccines
GB0801424D0 (en) Therapeutic vaccines
GB0919114D0 (en) Therapeutic intervention
ZA201107971B (en) Combined measles-malaria vaccine
GB0914545D0 (en) Vaccine
GB0907634D0 (en) Therapeutic device
GB0912579D0 (en) Therapeutic device
GB0913577D0 (en) Therapeutic device